bamadutide

Bamadutide (SAR425899) is a novel dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), developed for the treatment of obesity and type 2 diabetes mellitus. As a polypeptide drug, it acts by stimulating both GLP-1 and glucagon receptors, leading to improved glycemic control through enhanced β-cell function, slowed glucose absorption, reduced fasting plasma glucose and glycated hemoglobin levels, as well as significant weight loss in both healthy volunteers and patients with type 2 diabetes. Clinical studies demonstrated that bamadutide was generally well tolerated with gastrointestinal side effects being most common. The drug also increased lipid oxidation and reduced metabolic adaptation during weight loss[1][4][6].

Brand names

bamadutide

Other names

SAR425899SAR-425899SAR 425899